[go: up one dir, main page]

RU2016111619A3 - - Google Patents

Download PDF

Info

Publication number
RU2016111619A3
RU2016111619A3 RU2016111619A RU2016111619A RU2016111619A3 RU 2016111619 A3 RU2016111619 A3 RU 2016111619A3 RU 2016111619 A RU2016111619 A RU 2016111619A RU 2016111619 A RU2016111619 A RU 2016111619A RU 2016111619 A3 RU2016111619 A3 RU 2016111619A3
Authority
RU
Russia
Application number
RU2016111619A
Other versions
RU2016111619A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016111619A publication Critical patent/RU2016111619A/ru
Publication of RU2016111619A3 publication Critical patent/RU2016111619A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2016111619A 2013-08-30 2014-08-26 Способ лечения фиброзного заболевания RU2016111619A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1315486.9A GB201315486D0 (en) 2013-08-30 2013-08-30 Antibodies
GB1315486.9 2013-08-30
PCT/EP2014/068047 WO2015028454A2 (en) 2013-08-30 2014-08-26 Method for the treatment of fibrotic disease

Publications (2)

Publication Number Publication Date
RU2016111619A RU2016111619A (ru) 2017-10-05
RU2016111619A3 true RU2016111619A3 (ru) 2018-05-17

Family

ID=49397072

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016111619A RU2016111619A (ru) 2013-08-30 2014-08-26 Способ лечения фиброзного заболевания

Country Status (17)

Country Link
US (1) US20160200820A1 (ru)
EP (1) EP3039041B1 (ru)
JP (1) JP6618471B2 (ru)
KR (1) KR102346566B1 (ru)
CN (2) CN116036267A (ru)
AU (1) AU2014314303B2 (ru)
BR (1) BR112016004297B1 (ru)
CA (1) CA2920931C (ru)
CL (1) CL2016000436A1 (ru)
ES (1) ES2786260T3 (ru)
GB (1) GB201315486D0 (ru)
IL (1) IL244042B (ru)
MX (1) MX2016002179A (ru)
MY (1) MY181808A (ru)
RU (1) RU2016111619A (ru)
SG (1) SG11201601149TA (ru)
WO (1) WO2015028454A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
MA44309A (fr) * 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
WO2017176804A1 (en) * 2016-04-04 2017-10-12 Massachusetts Institute Of Technology Compositions of crystallized hydrophobic compounds and methods of making and using same
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
CN110575540B (zh) * 2018-06-07 2021-11-02 中山大学附属第六医院 Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途
WO2020159243A1 (ko) 2019-01-30 2020-08-06 한양대학교 산학협력단 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용
KR102356829B1 (ko) * 2019-01-30 2022-01-28 주식회사 에프엔씨티바이오텍 폐 섬유화 질환 진단 또는 치료를 위한, m-csf 또는 g-csf의 이용
KR102179518B1 (ko) 2019-03-29 2020-11-17 주식회사 혜안 황산염 자극에 의한 고로슬래그 활성화 무기 결합재 제조방법
EP3977397B1 (en) * 2019-05-24 2025-02-26 Pharmanest LLC Quantitative phenotyping of fibrosis from images of biological tissue samples
JP2024518602A (ja) 2021-05-17 2024-05-01 ノグラ ファーマ リミテッド Il-34アンチセンス剤およびそれを使用する方法
CN113350346B (zh) * 2021-06-01 2023-06-27 广西医科大学第一附属医院 长春新碱在预防或治疗心肌纤维化中的应用
WO2023091479A1 (en) * 2021-11-17 2023-05-25 AmMax Bio, Inc. Detection and treatment of idiopathic pulmonary fibrosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239728A1 (en) * 2002-07-31 2005-10-27 Pachuk Catherine J Double stranded rna structures and constructs, and methods for generating and using the same
GB0326393D0 (en) * 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
KR101200133B1 (ko) * 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
KR101289537B1 (ko) * 2005-02-15 2013-07-31 듀크 유니버시티 항-cd19 항체 및 종양학에서 이의 용도
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US20080032989A1 (en) * 2006-05-31 2008-02-07 Robinson William H Method of treating inflammatory diseases using tyroskine kinase inhibitors
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
EP3330292A1 (en) * 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
EP2241333A1 (en) * 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2010012667A1 (en) * 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
SG191129A1 (en) * 2010-12-13 2013-07-31 Array Biopharma Inc SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
KR102061358B1 (ko) * 2011-10-21 2019-12-31 트랜스진 에스.에이. 대식세포 활성화의 조절
MX2014008961A (es) * 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.

Also Published As

Publication number Publication date
BR112016004297A2 (pt) 2017-10-17
RU2016111619A (ru) 2017-10-05
JP2016529265A (ja) 2016-09-23
US20160200820A1 (en) 2016-07-14
IL244042B (en) 2020-07-30
KR102346566B1 (ko) 2021-12-31
BR112016004297B1 (pt) 2020-11-17
MX2016002179A (es) 2016-06-06
KR20160045891A (ko) 2016-04-27
EP3039041A2 (en) 2016-07-06
MY181808A (en) 2021-01-07
AU2014314303A1 (en) 2016-03-17
GB201315486D0 (en) 2013-10-16
IL244042A0 (en) 2016-04-21
ES2786260T3 (es) 2020-10-09
EP3039041B1 (en) 2020-03-04
AU2014314303B2 (en) 2019-11-21
WO2015028454A2 (en) 2015-03-05
CL2016000436A1 (es) 2016-11-18
CA2920931A1 (en) 2015-03-05
CN105612181A (zh) 2016-05-25
CN116036267A (zh) 2023-05-02
SG11201601149TA (en) 2016-03-30
WO2015028454A3 (en) 2015-05-21
CA2920931C (en) 2022-09-06
JP6618471B2 (ja) 2019-12-11

Similar Documents

Publication Publication Date Title
BR112015007533A2 (ru)
BR102016010778A2 (ru)
BR112014017733A2 (ru)
BR112014018502A2 (ru)
BR112014017739A2 (ru)
BR112014019326A2 (ru)
BR112014018480A2 (ru)
BR112014018516A2 (ru)
BR112014020341A2 (ru)
BR112014017855A2 (ru)
BR112014017765A2 (ru)
BR112014017669A2 (ru)
BR112014021878A2 (ru)
BR112016014393A2 (ru)
BR112014018468A2 (ru)
BR112014017901A2 (ru)
BR112014019204A2 (ru)
BR112014018207A2 (ru)
BR112016005760A2 (ru)
BR112015015948A2 (ru)
RU2016111619A3 (ru)
BR112014017722A2 (ru)
BR112014017653A2 (ru)
BR112014018578A2 (ru)
BR112014018483A2 (ru)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190514